By Maggie Fick and Stine Jacobsen LONDON/COPENHAGEN (Reuters) -Obesity drug maker Novo Nordisk forecast slower growth this ...

Veralto Corporation delivered all-time high annual sales of $5.2 billion in 2024, with 3.7% core sales growth and an adjusted earnings per share increase of 11% to $3.54. Free cash flow generation ...

Novo’s newest GLP-1, CagriSema, is the first big test of Novo Nordisk’s future as the leader in the obesity treatment market.

The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower ...

KMB's Q4 sales fell 0.8% y/y, with organic sales growth at 2.3%, but only 0.7% excluding hyperinflationary markets. Explore ...

Solid demand in rural areas, as well as higher prices of staples including edible oil and wheat flour, helped the consumer ...

Solid demand in rural areas, as well as higher prices of staples including edible oil and wheat flour, helped the consumer ...

The past two years have shown the power of investing in growth stocks. The S&P 500 has returned nearly 60% during that time, ...

The COVID-19 pandemic dealt a severe blow to both cruise and air travel industries. The mere thought of traveling in a closed ...

Pernod Ricard has cut its sale guidance because of uncertainty over tariffs and a slowdown in China, where government anti-dumping measures have hit demand for its cognac brand Martell.

Qualcomm on Wednesday forecast sales and profits above analyst expectations as artificial intelligence features helped fuel ...

Survey by SIDBI shows MSMEs in manufacturing, trading, and services sectors optimistic about business performance and future ...